CARGO Therapeutics

📍 San Mateo, United States🗓 Founded 2021👥 57 employees💰 Last funded Jan 2021
Biotechnology Research🌐 cargo-tx.com
Website LinkedIn
CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in CARGO Therapeutics?
CARGO Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did CARGO Therapeutics last raise funding?
The most recent investment in CARGO Therapeutics recorded on gritt.io was in January 2021.
When was CARGO Therapeutics founded?
CARGO Therapeutics was founded in 2021.
What industry is CARGO Therapeutics in?
CARGO Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is CARGO Therapeutics based?
CARGO Therapeutics is headquartered in San Mateo, United States.